MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law.

Business Wire • Aug 8, 2026

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options

GlobeNewsWire • Aug 7, 2026

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Myriad Genetics (MYGN)

Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Street's $206-$208 million -- and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses. Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Street's $206-$208 million -- and MYGN shareholders took the hit. Levi & Korsinsky is investigating potential securities law violations on behalf of MYGN investors who suffered losses.

GlobeNewsWire • Aug 6, 2026

MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

GlobeNewsWire • Aug 6, 2026

MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)

NEW YORK--(BUSINESS WIRE)--On May 5, 2026, Myriad Genetics (NASDAQ: MYGN) reaffirmed adjusted EBITDA of $37 million to $49 million and adjusted gross margin of 68% to 69% for full-year 2026. Roughly three months later, the adjusted EBITDA range was suspended outright and MYGN shares dropped. If you held Myriad Genetics stock and lost money, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (2.

Business Wire • Aug 5, 2026

Myriad Genetics, Inc. (MYGN) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely disclose material information to investors.

GlobeNewsWire • Aug 4, 2026

Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)

On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just three months later, the Company cut guidance to $770-$790 million and adjusted EBITDA guidance was suspended -- and MYGN shareholders absorbed the loss.

PRNewsWire • Aug 3, 2026

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 31, 2026

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and executing revenue cycle initiatives expected to improve reimbursement predictability and performance.

GlobeNewsWire • Jul 30, 2026

Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates

Myriad Genetics (MYGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.05 per share a year ago.

Zacks Investment Research • Jul 30, 2026